![]() | ![]() |
Formats:
|
||||||||||||||||||||||||||||||||
Copyright © 2007 Cekaite et al; licensee BioMed Central Ltd. Mapping of oxidative stress responses of human tumor cells following photodynamic therapy using hexaminolevulinate 1Department of Tumor Biology, Rikshopitalet – Radiumhospitalet Medical Center, 0310 Oslo, Norway 2Department of Pathology, Rikshopitalet – Radiumhospitalet Medical Center, 0310 Oslo, Norway 3State Key Lab for Advanced Photonic Materials and Devices, Fudan University, Shanghai, P.R. China Corresponding author.Lina Cekaite: linac/at/rr-research.no; Qian Peng: qpeng/at/ulrik.uio.no; Andrew Reiner: andrew.reiner/at/imbv.uio.no; Susan Shahzidi: susan.shahzidi/at/labmed.uio.no; Siri Tveito: Siri.Tveito/at/rr-research.no; Ingegerd E Furre: ingegere/at/extern.uio.no; Eivind Hovig: ehovig/at/ifi.uio.no Received December 20, 2006; Accepted August 13, 2007. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background Photodynamic therapy (PDT) involves systemic or topical administration of a lesion-localizing photosensitizer or its precursor, followed by irradiation of visible light to cause singlet oxygen-induced damage to the affected tissue. A number of mechanisms seem to be involved in the protective responses to PDT, including activation of transcription factors, heat shock proteins, antioxidant enzymes and apoptotic pathways. Results In this study, we address the effects of a destructive/lethal hexaminolevulinate (HAL) mediated PDT dose on the transcriptome by using transcriptional exon evidence oligo microarrays. Here, we confirm deviations in the steady state expression levels of previously identified early defence response genes and extend this to include unreported PDT inducible gene groups, most notably the metallothioneins and histones. HAL-PDT mediated stress also altered expression of genes encoded by mitochondrial DNA (mtDNA). Further, we report PDT stress induced alternative splicing. Specifically, the ATF3 alternative isoform (deltaZip2) was up-regulated, while the full-length variant was not changed by the treatment. Results were independently verified by two different technological microarray platforms. Good microarray, RT-PCR and Western immunoblotting correlation for selected genes support these findings. Conclusion Here, we report new insights into how destructive/lethal PDT alters the transcriptome not only at the transcriptional level but also at post-transcriptional level via alternative splicing. Background Photodynamic therapy (PDT) combines a light-activated drug with non-thermal light to cause selective damage to the target tissue [1]. The major mechanism of action of PDT has been shown to be induction of oxidative stress [2,3]. It has also been shown that PDT-mediated oxidative stress induces a transient increase in the early response genes FOS, JUN, MYC, and EGR1 [4,5], heat shock proteins (HSPs) [6-9], as well as SOD2, LUC7A, CASP8, and DUSP1 [10]. Furthermore, relevant information exists regarding specific gene expression patterns regulated by oxidative stress [5,11-18]. Signaling pathways influenced by PDT have not been fully elucidated, although a number of studies have addressed this issue [5,10,19]. Moreover, relatively little is known regarding global gene activity, particularly when oxidative stress becomes excessive, as is the case for PDT. Both clonogenic survival of cells from tumors after in vivo PDT treatment [20] and resistance to aminolevulinic acid (ALA)-mediated PDT [21] have been reported previously. Intrinsic cell sensitivity to PDT has been proposed [20] to be an important component in the mechanism that leads to tumor response following PDT treatment in vivo. A better understanding of the mechanics of the destructive PDT could facilitate further the development of this therapy. Oxidative stress evokes many intracellular events including apoptosis [22]. Modulating the anti-apoptosis factors that are activated by survival signaling may improve efficacy of the therapy. Under conditions where oxidative stress is the initiating stimulus for apoptosis, it is assumed to simply trigger cell death as a result of cumulative oxidative damage. However, accumulating evidence now suggests that reactive oxygen species (ROS) may act as signaling molecules for the initiation and execution of the apoptotic death program in many, if not all, current models of apoptotic cell death [23,24]. Signaling by ROS would not appear to be random, as previously assumed, but targeted at specific metabolic and signal transduction cellular components [25]. Here, we address the effects of a destructive/lethal PDT dose on the transcriptome by using transcriptional exon evidence oligo microarrays. This dose induces high levels of cytotoxicity and is expected to have significant impact on gene expression patterns. The expression alterations were observed by investigating both early responses, and responses post mobilization of major response pathways. We show that high levels of cellular cytotoxicity have a direct effect on cellular transcription levels and impair metabolic processes. Alternative splicing represents a key event in the control of gene expression [26-30]. Here, we tested to what extent mitochondrial damage caused by HAL-PDT modulates alternative splicing in a global manner. Results and discussion Rationale for selection of experimental parameters Sensitizer 5-Aminolevulinic acid (ALA), a precursor to porphyrins, is effective and widely used for PDT of a number of diseases [31-34]. However, a significant shortcoming of ALA is its limited ability to cross certain biological barriers (e.g. cellular membranes), probably due to its low lipid solubility. In contrast, ALA esters are more lipophilic and pass more easily through biological membranes than ALA itself. Hexaminolevulinate (HAL) is a hexyl ester of ALA with a higher lipophilicity. HAL has been shown to be 50–100 times more efficient than ALA at inducing cellular porphyrin formation with a high selectivity [35], and has been approved by the European Union for photodetection of bladder cancer. Thus, HAL is a promising compound for PDT therapy. On this basis, it is reasonable to assume that the mechanisms of action of ALA and HAL are comparable, and that gene expression profiles should be very similar. Therefore, only HAL was chosen for this study. Cell line Studies are now in progress to test the use of PDT for several types of pre-cancerous conditions and cancer, including cancers of the skin, cervix, bladder, prostate, bile duct, pancreas, stomach, brain, head and neck, as well as lymphoma. PDT using topically applied ALA was first reported for the treatment of cutaneous T-cell lymphoma (CTCL) in 1994. Since then, there have been several reports of its usefulness in treating this disease [33,36-39]. The role of PDT in CTCL to date has been in the treatment of individual patches, plaques, and tumors that have not responded to the other forms of skin directed therapy. While several PDT protocols have been evaluated, further studies remain in order to define the optimal use of PDT in treating patients with CTCL. Moreover, the use of PDT for ex vivo purging of autologous bone marrow graft has been proposed [40]. High-dose chemotherapy supported by hematopoietic stem cells transplantation (HSCT) presents an effective way to cure lymphoma/leukemia. Although autologous HSCT has several advantages over allogenous HSCT, autografts may harbor residual occult malignant cells that can cause a tumor relapse after being reinfused to the patient. It is therefore desirable to remove the residual neoplastic cells from the autograft before being applied. The ability of malignant cells to selectively accumulate photosensitizers offers the possibility of using PDT in bone marrow purging. Recently, a study of the purging effects of PDT in leukemic cells mixed with normal bone marrow MNCs was published [41]. Here, we aimed to map general responses on gene expression after PDT therapy. Therefore we employed the Jurkat human T-cell leukemia cell line that previously has been used in multiple PDT-studies. The induction of apoptosis through translocation of apoptosis-inducing factor [42,43] and caspase-3-like activation has been demonstrated for this cell line. Also, other sensitizers in PDT therapy have been shown to induce apoptosis in Jurkat cells [32,44-46]. Dose and time course The aim of this study was to determine the gene expression state of the cell in response to PDT immediately prior to and post switching to the programmed cell death. Here, we measured gene signatures that were likely to represent a combination of both protective and pro-apoptotic signals. The characterization of the transcriptome at early stages (1 h and 2 h) was chosen to reveal the state of the cell prerequisites to the execution of the cell death program. It has been previously demonstrated that the appearance of cytoplasmic mRNA degradation products occur 4–8 h after induction of apoptosis, independent of the apoptotic signal and the cell line used [47]. The purity and integrity of the RNA are critical for the overall success of RNA-based analysis, including gene expression profiling. For this reasons, the late (4 h) time point was selected to provide an insight into the later stages of this process, but still retain a sufficient numbers of viable cells and RNA integrity necessary for the technical execution of the analysis. In this study, the integrity of total RNA was measured by microcapillary electrophoresis and the degree of degradation was determined (data not shown). With the starting amount of cells kept equal across experiments, a time dependent decrease of the total amount of isolated total RNA was obtained. No compromise in the integrity of the RNA was observed. This indicates the effective removal of the dead cell fraction by the wash/centrifugation step, following degradation of leaked RNA. PDT is a cytotoxic therapy approach, where the dose in therapeutic settings is selected to kill 100% of the target cells. Therefore, a lethal dose (LD) relevant to therapeutic settings was chosen for the study. Lethal and sub lethal doses have been employed in a number of reports that investigated the apoptotic pathways induced by PDT [42,43,48]. The cell survival after HAL-PDT was determined to select the killing dose specific for the Jurkat cell line. Fig. Fig.1A1A
Overview of transcriptome changes For gene expression analysis, Jurkat cells were treated with HAL-PDT, and total RNA was harvested from triplicate samples of non-treated and treated cells at 1, 2 and 4 h after HAL-PDT. Gene expression levels in HAL-PDT treated cells relative to non-treated cells were determined by oligo microarrays that contained a total of 44,308 oligos targeting human genes. The Venn diagram shows that 146 probes (103 unique Entrez gene IDs) exhibited significant changes (p < 0.05) 1 h after HAL-PDT treatment (Fig. (Fig.2A).2A
Early responses A total of 170 probes (124 unique Entrez gene IDs) were altered at early (1 and 2 h) response (Fig. (Fig.2A).2A Of the total of 170 probes detected as altered at the two early time points, 44 probes (32 unique Entrez gene IDs) were identified as shared for both the 1 h and 2 h time points in response to HAL-PDT. Among the early response genes, mostly genes encoding proteins involved in the regulation of transcription processes were induced, such as v-jun sarcoma virus 17 oncogene homolog (avian) (JUN), jun B proto-oncogene (JUNB), v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) (MAFB), RNA-binding region (RNP1, RRM) containing 2 (RNPC2), SRY (sex determining region Y)-box 4 (SOX4), tribbles homolog 3 (Drosophila) (TRIB3), Kruppel-like factor 6 (KLF6), zinc finger protein 184 (Kruppel-like) (ZNF184), activating transcription factor 3 (ATF3), BTG family, member 2 (BTG2). While inhibitor of DNA binding 3, dominant negative helix-loop-helix protein (ID3) and v-myc myelocytomatosis viral oncogene homolog (avian) (MYC) were down-regulated. Consistent with gene expression data, the protein products of MYC were found to be reduced, while JUN had increased levels at 2 h and 4 h after HAL-PDT (Fig. (Fig.3).3
Histone related genes Of the 170 probes detected as early genes (124 unique Entrez gene IDs), 53 genes were identified as involved in nucleosome assembly and belonged to the histone family of genes (Fig. (Fig.4).4
Metallothioneins The family of metallothioneins was highly represented as differentially expressed (10 genes) (Fig. (Fig.6).6
Late responses Contrary to early responses, the number of altered genes/probes increased sharply to a total of 15,762 probes (10,373 unique Entrez gene IDs) at 4 h, clearly displaying the massive disturbances in the transcriptome within the pro-apoptotic cells. The proportion of genes with up-regulated expression decreased to 41.1% at 4 h, compared to 82.9% of up-regulated genes at early response. Since the destructive PDT dose likely causes high levels of oxidative stress, we cannot neglect that the high number of altered genes might likely indicate random transcriptome changes, caused by direct oxidation of non-specific mRNAs [63]. RNAs are reported to be more sensitive to photodynamic degradation than DNA [56], especially since most RNAs are cytoplasmic and exposed to higher ROS concentrations. In the case of RNA molecules themselves are photooxidative targets, one could expect that the mRNA transcripts would be damaged randomly and not bind to the specific probes on microarrays. As a result, the expression of genes will be measured as down regulated compare to untreated cells. To explore whether the observed RNA down-regulation at 4 h was direct and non-specific, or targeted, we performed a Gene Ontology and KEGG analysis. We observed that down-regulated genes contributed significantly in GO enriched groups within the total of differentially expressed genes (Table 1, 2). While up-regulated genes scored in other GO groups, a number of enriched extra-nuclear processes, especially mitochondrial, were present when down-regulated genes were scored. However, since HAL, the mitochondrial localizing sensitizer was used in the study [43,64-67], the direct effect on mitochondria was expected. Furthermore, enriched GO processes of up-regulated genes included both nuclear and extra-nuclear processes, such cytoskeleton, junctions and adhesion. Notably, because of the direct PDT effect to cytoskeleton, well-known house keeping proteins such actin or tubulin that is widely used for the quantitation of western data would not be representative controls. Thus, for western blots, the total protein content was used as a measure, by staining the gels after electrophoresis and signals normalized against total protein content. Interestingly, genes encoded proteins in the porphyrin metabolism were stimulated, indicating cellular response to excessive porphyrin production after the transfection with HAL, which is a heme precursor. Among these genes, 7 different UDP glucuronosyltransferase 1 and 2 family genes were induced. These are of major importance in heme degradation [68,69]. The gene ontology analysis suggested that the cell commitment to apoptosis was directly reflected in the transcriptome in a specific manner, and not random changes.
Oxidative stress/mitochondria A total of 639 probes (418 unique Entrez gene IDs) from genes relevant to mitochondrial function were identified as altered, of which 78.1% were down-regulated. These genes encoded components of the mitochondrial envelope, the mitochondrial membrane, inter membrane, lumen and ribosome, as well as the proton-transporting ATPase complex. The mitochondrial localization of ALA or HAL-induced protoporphyrin-IX (PpIX) has been established [43,64-67]. The ultrastructural alterations of the mitochondria, in addition to higher percentages of cells losing the mitochondrial transmembrane potential, was reported following ALA-PDT [42,65,67]. A total of 101 genes altered by HAL-PDT were identified as being involved in oxidative phosphorylation (Table 1). This gene ontology group was the group most significantly (p = 9.1E-10) enriched among all gene groups. A total of 32 genes from the ATP synthesis coupled electron transport were found to be altered, the majority being down-regulated. This is consistent with previously published data, where ATP levels were found to be decreased at both 1 and 4 h after ALA-PDT [65]. Furthermore, dysregulation of the citrate cycle (TCA cycle) indicated that the cell energy balance was seriously damaged. Surprisingly, a majority of the mitochondrial nuclear encoded genes were found to be down-regulated, while mitochondrial encoded genes (23 genes) were found to be up-regulated at 4 h (Fig. (Fig.7).7
The combination of the cellular responses (induction of histones and metallothioneins) in addition to induction of mitochondrial encoded genes may indicate a partial repair of mitochondrial and other cellular functions. However, it is in general difficult to assess the impact of the changes in gene expression at 4 h, as cell mortality is the endpoint. One of the reasons could be damaged translational machinery, given that ribosomal proteins were identified as direct targets (Tables 1, 2). Other pathways/genes Other gene ontology processes found to be very significantly affected included those of the ribosome, cell cycle genes, proteosome, ubiquitin mediated proteolysis (Table 1), as well as protein transport, and ER to Golgi vesicle mediated transport (data not shown). This indicated that main cellular processes, such as the cell cycle and protein synthesis/transport were disrupted, leading to protein degradation through ubiquitine mediated proteolysis. In addition, the processes such pyrimidine and purine metabolism, glycolysis/gluconeogenesis, RNA/DNA metabolism, cellular protein metabolism, protein biosynthesis scored highly among enriched gene ontology groups indicating disruption of these processes. This seems to be an indication that the basic energy metabolism is shutting down, or at least is heavily affected, as one should expect from apoptotic cells. Effect on alternative splicing In our experiments, we observed that HAL-PDT resulted in expression changes in the spliceosome complex. A total of 72 probes (44 unique Entrez gene IDs) showed significant changes at 4 h (Table 2), while expression of 39 genes were down-regulated (Fig. (Fig.8).8
Correspondence between alternative microarray platforms: cDNA and oligo microarrays Molecular confirmation of microarray results is important when checking for consistencies of expression measurements using different methods. RT-PCR and Western blotting were used for selected genes. Recently, different microarray platforms have been reported to have a good agreement [79,80]. Therefore, we included experiments on one of the time points (1 h) performed on cDNA microarrays. In agreement with oligo microarrays, top ranking of the genes showed alteration in ATF3, CERBPB, JUN, JUND, IER2, as well as metallothioneins and histone coding genes (Table 5).
Conclusion In summary, the results provided new insights into how a PDT relevant dose alters gene expression. We confirmed known early defense response genes, and extended these to include the involvement also of other oxidative stress inducible gene groups, most notably the metallothioneins and histones. We also demonstrated that high levels of cellular cytotoxicity had direct effects on nuclear and mitochondrial DNA transcription levels in impairing metabolic processes. Furthermore, we attempted to identify how different signaling processes may be involved in the execution of cell death. The results indicated that mitochondrial damage caused by HAL-PDT modulates alternative splicing through unbalancing a vast number of isoform equilibriums, which may be an important contribution to the deadly outcome of HAL-PDT therapy. Methods Cell culture and PDT treatment The human T-cell leukemia cell line, Jurkat, was maintained in RPMI 1640 medium containing 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 μg/ml streptomycin and 1% glutamine in a fully humidified incubator (Nuaire US Autoflow) at 37°C with 5% CO2. In experiments with PDT, 8 × 105/ml of cells were seeded in 6-well plastic tissue-culture plates (Nunc) and incubated in the dark for 4 h in serum-free RPMI 1640 medium containing 5 μM of hexaminolevulinate (HAL) (PhotoCure ASA, Oslo, Norway). Since the light penetration is undemanding for the cell line, the light source used in the present study has a broad spectrum with a range of 400–500 nm, fitting largely to the maximal absorption of porphyrins derived from ALA and its esters including HAL. Our previous studies have shown that the combination of HAL with the light source can kill various types of tumor cells efficiently [42,43]. The cells were exposed to light from a bank of four fluorescent tubes (model 3026, Applied Photophysics, London, UK). The fluence rate of the light reaching the cells was 8 mW/cm2. The light doses of 80, 160 and 240 mJ/cm2 were used to determine the cell viability. The light dose of 160 mJ/cm2 was chosen to treat the cells used in microarray experiments. The cells were washed twice with medium immediately after illumination and incubated with fresh medium containing 10% FCS. Cells were washed twice with PBS before sampling. Cell survival Cell survival was measured by the MTS assay [81]. After HAL-PDT, 100 μl of each sample was placed to 96-well plastic microplates (Nunc) and incubated at 37°C for 0, 1 and 3 h, followed by the addition of 20 μl of MTS (5 mg/ml) (Promega Corporation, Madisom, WI, USA) into each well for an additional 1 h-incubation. The absorbance at 490 nm was measured with a microplate reader (Labsystems Oy, Helsinki, Finland). The absorbance of blank wells containing medium and MTS, but no cells, was subtracted from all readings and cell survival was expressed as the fraction of control samples. RNA purification and labelling Total RNA was isolated using GenElute Mammalian Total RNA kit (Sigma, St. Louis, MO) according to the manufacturer's protocol. RNA concentrations were determined with NanoDrop spectrophotometer (NanoDrop Technologies). The integrity and degree of degradation of RNAs was calculated using Agilent 2100 Bioanalyzer (Agilent Technologies AS). Fluorescence-labelled cDNAs were synthesized from 20 μg of the total RNA using an indirect amino allyl microarray labelling kit (Faiplay, Stratagene, La Jolla, CA, USA) according to the manufacturer's recommendations. Oligo microarrays and their hybridization The oligo microarrays used in this study were obtained from The Norwegian Microarray Consortium, for details on the arrays, we refer to [82]. The target oligos were the HEEBO (Human Exonic Evidence Based Oligonucleotide) set (Invitrogen). Probes included probes for constitutive, alternative exonic; alternative spliced/skipped exons, mitochondrial genes (mtDNA) for more details on oligos, we refer to [83]. During analysis all probes were handled individually, also those that encoded the same gene. The microarray hybridization buffer (76 ul) contained each of the labeled probes, 16 μg poly A (Amersham Pharmacia Biotech AB), 8 μg yeast tRNA, 0.5 μg herring's sperm DNA, 5 × SSC, 0,1% SDS, 25% (v/v) formamid. Prior to hybridization, the solution was incubated for 2 min at 100°C and then centrifuged for 2 min at 13,000. The microarray slides were hybridised at 42°C overnight in a humid hybridization chamber (TeleChem International, Inc.). The slides were washed for twice in 0.5× SSC, 0.01% SDS, and 0.06× SSC for 5 min at room temperature. The slides were spun and dried immediately after washing. The microarray experiment design was based on competitive hybridizations of HAL-PDT treated cells vs untreated. Total RNA was harvested from triplicate samples of treated and non-treated cells at 1, 2 and 4 h after HAL-PDT. Three replicated hybridization were performed for each time point. cDNA microarays and their hybridization The cDNA microarrays used in this study were obtained from The Norwegian Microarray Consortium, for details on the arrays, we refer to [82]. The targets, approximately 15.000 unique I.M.A.G.E cDNA clones were from ResGen 40 k set. The hybridization volume of 110 μl consisted of: 8–10 μl of each of the labelled probes, 16 μg poly A (Amersham Biosciences), 15 μg human Cot-1 DNA (Invitrogen) and 85–90 μl of Microarray Hybridization Buffer #1 from Ambion (Austin, TX). The final mix was heated for 2 min at 100°C and after spinning down it was applied on a microarray. A hybridization station (Genomic Solutions, Inc., Ann Arbor, MI) was used for hybridization and wash, the details on hybridizations and wash can be found [82]. Data preparation and analysis Slides were scanned using an Agilent Microarray scanner (Agilent Biotechnologies). The quantitative measurements of the fluorescence images were performed by the software GenePix 4000B (Axon Instruments, Union City, CA). The images (TIFF files) and extracted raw data (GRP files) were stored in a BASE 1.2.15 database [84]. The spots that were technically flawed or flagged automatically by the GenePix software, spots with a diameter less than 60 μm were removed from the data of each microarray. The genes were preserved signal-to-noise ratio in one of the channel was equal or higher then 3 removing uncertain spots. Background-subtracted intensities less than one times the sdtev of the local background were assigned this value to avoid zero or negative values in the ratio calculations. Moreover, systematic errors were corrected by normalizing the data using a locally weighted scatter plot smoother, the method of pin-based lowess[85] The genes were preserved if the values were experimentally obtained in more than 70% of the experimental matrix. The weighted K-nearest neighbours method was applied for imputation of missing values [86]. We used Limma package in R [87] to define differentially expressed genes. As we had three groups (1, 2 and 4 h) and three replicates in each group, the linear model fitting and empirical Bayes methods were used for assessing differential expression. The empirical Bayes approach is equivalent to shrinkage of the estimated sample variances towards a pooled estimate, resulting in far more stable inference when the number of arrays is small [88]. To classify a series of related t-statistics as up, down or not significant, the multiple testing across genes and contrasts (1, 2 and 4 h groups) was used. To avoid the multiple testing problem [89] we have used Benjamine and Hochberg's method [90] to control the false discovery rate across the genes with restriction p < 0.05. The venn diagrams were prepared with Limma to visualize the intersections of the significant gene sets within groups. Hierarchical clustering of genes for visualisation of expression patterns was performed in MultiExperiment Viewer (MEV) [91]. Functional classification was performed by using the Database for Annotation, Visualization and Integrated Discovery (DAVID, release 2.1) online tools. The relative enrichment of KEGG pathways (KEGG PATHWAY Database (July 19, 2006)) was calculated the number of genes, belonging to these functional categories in the list of significantly altered genes. The gene-enrichment of functional pathways measured by determining the number of genes, belonging to the pathway in the list of significantly altered genes weigh against to the total analysed/printed genes on arrays (background) using Fisher Exact test. For top raking of the genes, only 1 h post HAL-PDT experiments performed cDNA and oligo arrays were taken. The join was done using locus link IDs, so a gene appears as ranked only if locus links IDs present for both the cDNA and oligo significantly altered genes. Since many oligo probes map to the same locus link, the highest-ranking oligo probe for a particular locus link is used in the ranking. Gel electrophoresis and immunoblotting For protein isolation, the cell pellets were lysed on ice in 1 ml of lysis buffer (0.4% w/v SDS, 5 mM EDTA, 5 mM EGTA, 10 mM sodium pyrophosphate and 20 mM Tris-base; pH 7.2) for 30 min, briefly sonicated, diluted 1:2 in double strength SDS gel-loading buffer [double strength, 1% (w/v) SDS, 4.8 mM sodium deoxycholate, 10% (v/v) mercaptoethanol, 1% (v/v) Igepal CA-630, ~0.1% (w/v) Bromophenol Blue, 13,4% (v/v) glycerol and 120 mM Tris/HCl, pH 6.8] and boiled for 5 min at 95°C. After measuring the protein contents of the extracts with the BCA protein assay kit from Pierce (Rockford, USA) [92], 10 μg of samples were separated by SDS gel electrophoresis for 40 min at 200 V in 10% polyacrylamide gels containing 0.1% SDS. Molecular weight markers were included in all gels. Gel-separated proteins were transferred to nitrocellulose blotting membranes using a semi-dry transfer unit (Bio-Rad Laboratories, Hercules, CA, USA) with Towbin's blotting buffer (192 mM glycine, 20% methanol and 25 mM Tris-base; pH 8.3). The membranes were blocked by overnight incubation with 5% dry milk in TBS containing 0.2% Tween-20 (TBS-T) at 4°C, and washed three times for 10 min each in TBS-T. For detection of proteins, the membranes were incubated with the antibodies of MYC, ATF3 and JUN (diluted 1:1000 in TBS-T) overnight at 4°C, washed three times with TBS-T and incubated with the respective anti-rabbit or mouse-horseradish peroxidase-conjugated secondary antibodies (diluted 1:2000 in TBS-T) for 1 h at room temperature before being visualized by chemiluminescence using an ECL Western Detection Kit (Amersham Biosciences). To verify optimal blotting condition, the remaining proteins in the polyacrylamide gels were routinely stained with coomassie solution (0.1% (w/v) Coomassie blue R350, 20% (v/v) methanol, and 10% (v/v) acetic acid) for 2 hours and excess staining was removed by using a destaining solution (50% (v/v) methanol in water with 10% (v/v) acetic acid) over night. RT-PCR The same source of total RNAs (as in the microarray experiments) was used for real-time RT-PCR validation of selected genes. cDNA was synthesized from 1 μg DNase I-treated RNA using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). The cDNA solution was diluted 1:3 or 1:6 with nuclease-free water. Real-time PCR was performed using the iQ SYBR Green supermix (Bio-Rad) and specific primer pairs for the selected genes (specified in Fig. Fig.55
Splicing analysis A program was written to create a concordance between locuslink IDs and HEEBO constitutive and alternative exon probes, using annotation information provided with the HEEBO probe set. This concordance grouped each locuslink ID with the oligo IDs of the probes targeting the exons contained within the locus. For a each locus L, we applied a test to determine if there was a difference in expressed spliced isoforms between the treated and reference sample. At a hybridization at a given timepoint, we searched for at least one probe A derived from an alternatively expressed exon in L such that 1) The absolute value of log2ratio (A) was above a given threshold (fold change of PDT treated vs. none treated controls by 1 and 2) there existed a probe C in L from derived from a constitutive exon such that the absolute value of the difference between the log2ratios of A and C was equal to or greater than 1. Thus, for each hybridization, we found a (possibly empty) set of alternatively-expressed exon probes for each locus L. Since we performed three hybridizations are each timepoint, we required at least two of the three to agree in their results. Specifically, we required that there be a non-empty intersection between the set of alternatively-expressed exon probes from at least two experiments at the timepoint. Abbreviations PDT, photodynamic therapy; HAL, hexaminolevulinate; ALA, 5-aminolevulinic acid; FDR, false discovery rate, GO; gene ontology; ROS, reactive oxygen species; KEGG, Kyoto Encyclopedia of Genes and Genomes. Authors' contributions LC performed microarrays, carried out the statistical and GO analysis, drafted and edited the manuscript. QP responsible for the study design regarding PDT performance, contributed in manuscript revision. AR carried out splicing and ranking analysis. SS run PDT experiments. ST planned RT-PCR experiments, designed primers, tested housekeeping genes and helped with RT-PCR analysis. IEF performed cell viability after PDT tests. EH conceived the study, guided the practical work, data analysis and revised the manuscript. All authors read and approved the final manuscript. Additional file 1 A total list of altered splice variants after HAL-PDT. The data provided represent the modulated alternative variants after 1, 2 and 4 h post HAL-PDT. Click here for file(231K, xls) Acknowledgements The present work was supported by The Norwegian Cancer Society. The microarrays were obtained through the Norwegian Microarray Consortium currently supported by the Functional Genomics Programme and the Research Council of Norway. We also thank to Michael T.N. Møller for performing western blots, Ane Sager Longva for doing RT-PCRs and Timothy J. Lavelle for the critical reading of the manuscript. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||||||||
J Natl Cancer Inst. 1998 Jun 17; 90(12):889-905.
[J Natl Cancer Inst. 1998]Cancer Res. 1991 Dec 15; 51(24):6574-9.
[Cancer Res. 1991]Photochem Photobiol. 1993 Sep; 58(3):374-9.
[Photochem Photobiol. 1993]Cancer Res. 1994 Mar 1; 54(5):1374-80.
[Cancer Res. 1994]Int J Oncol. 2002 Dec; 21(6):1353-9.
[Int J Oncol. 2002]Antioxid Redox Signal. 2002 Jun; 4(3):405-14.
[Antioxid Redox Signal. 2002]Biochimie. 2002 Feb-Mar; 84(2-3):131-41.
[Biochimie. 2002]Immunity. 1999 Jun; 10(6):735-44.
[Immunity. 1999]J Photochem Photobiol B. 2003 Feb; 69(2):71-85.
[J Photochem Photobiol B. 2003]Nucleic Acids Res. 2002 Sep 1; 30(17):3754-66.
[Nucleic Acids Res. 2002]Curr Opin Genet Dev. 1993 Aug; 3(4):574-84.
[Curr Opin Genet Dev. 1993]Cancer. 1997 Jun 15; 79(12):2282-308.
[Cancer. 1997]Exp Dermatol. 2005 Jun; 14(6):429-37.
[Exp Dermatol. 2005]J Urol. 2003 Jul; 170(1):226-9.
[J Urol. 2003]Br J Dermatol. 1994 Jun; 130(6):743-51.
[Br J Dermatol. 1994]J Am Acad Dermatol. 1994 Oct; 31(4):678-80.
[J Am Acad Dermatol. 1994]Clin Exp Dermatol. 2002 Sep; 27(6):516-8.
[Clin Exp Dermatol. 2002]Semin Oncol. 1994 Dec; 21(6 Suppl 15):24-7.
[Semin Oncol. 1994]Chin Med J (Engl). 2005 Jan 20; 118(2):105-10.
[Chin Med J (Engl). 2005]Cancer Res. 2005 Dec 1; 65(23):11051-60.
[Cancer Res. 2005]Apoptosis. 2006 Nov; 11(11):2031-42.
[Apoptosis. 2006]J Cutan Med Surg. 2001 Jan-Feb; 5(1):8-13.
[J Cutan Med Surg. 2001]Photochem Photobiol. 2002 Aug; 76(2):224-31.
[Photochem Photobiol. 2002]Arch Biochem Biophys. 2001 Jun 1; 390(1):57-63.
[Arch Biochem Biophys. 2001]FASEB J. 2002 Dec; 16(14):2003-5.
[FASEB J. 2002]Cancer Res. 2005 Dec 1; 65(23):11051-60.
[Cancer Res. 2005]Apoptosis. 2006 Nov; 11(11):2031-42.
[Apoptosis. 2006]J Environ Pathol Toxicol Oncol. 2006; 25(1-2):159-71.
[J Environ Pathol Toxicol Oncol. 2006]FEBS Lett. 2006 Oct 16; 580(24):5739-46.
[FEBS Lett. 2006]Gene. 2001 Jul 25; 273(1):1-11.
[Gene. 2001]Radiat Res. 1997 Aug; 148(2):188-92.
[Radiat Res. 1997]Toxicol In Vitro. 2005 Oct; 19(7):971-4.
[Toxicol In Vitro. 2005]Biochem Biophys Res Commun. 2006 Apr 14; 342(3):894-901.
[Biochem Biophys Res Commun. 2006]Photochem Photobiol. 1991 Apr; 53(4):549-53.
[Photochem Photobiol. 1991]Cancer Chemother Pharmacol. 2006 Sep; 58(3):408-14.
[Cancer Chemother Pharmacol. 2006]Toxicology. 1999 Feb 15; 132(2-3):85-98.
[Toxicology. 1999]Chem Biol Interact. 1995 May 19; 96(2):143-55.
[Chem Biol Interact. 1995]In Vitr Mol Toxicol. 2001 Fall; 14(3):219-31.
[In Vitr Mol Toxicol. 2001]Cancer Res. 1991 Dec 15; 51(24):6574-9.
[Cancer Res. 1991]Cancer Res. 1996 May 15; 56(10):2355-60.
[Cancer Res. 1996]Biol Chem. 2005 Apr; 386(4):333-7.
[Biol Chem. 2005]Carcinogenesis. 2001 May; 22(5):771-8.
[Carcinogenesis. 2001]Apoptosis. 2006 Nov; 11(11):2031-42.
[Apoptosis. 2006]Photochem Photobiol. 1997 Jan; 65(1):166-76.
[Photochem Photobiol. 1997]Lasers Surg Med. 2005 Jun; 36(5):398-408.
[Lasers Surg Med. 2005]Apoptosis. 2006 Nov; 11(11):2031-42.
[Apoptosis. 2006]Photochem Photobiol. 1997 Jan; 65(1):166-76.
[Photochem Photobiol. 1997]Lasers Surg Med. 2005 Jun; 36(5):398-408.
[Lasers Surg Med. 2005]Cancer Res. 2005 Dec 1; 65(23):11051-60.
[Cancer Res. 2005]J Photochem Photobiol B. 2006 Sep 1; 84(3):213-20.
[J Photochem Photobiol B. 2006]Curr Opin Genet Dev. 1993 Aug; 3(4):574-84.
[Curr Opin Genet Dev. 1993]Curr Opin Genet Dev. 1997 Apr; 7(2):205-11.
[Curr Opin Genet Dev. 1997]J Cell Biol. 2000 Apr 17; 149(2):307-16.
[J Cell Biol. 2000]Annu Rev Genet. 1998; 32():279-305.
[Annu Rev Genet. 1998]J Biol Chem. 1996 Jan 19; 271(3):1695-701.
[J Biol Chem. 1996]Nat Biotechnol. 2006 Jul; 24(7):832-40.
[Nat Biotechnol. 2006]Nat Biotechnol. 2006 Sep; 24(9):1151-61.
[Nat Biotechnol. 2006]Cancer Res. 2005 Dec 1; 65(23):11051-60.
[Cancer Res. 2005]Apoptosis. 2006 Nov; 11(11):2031-42.
[Apoptosis. 2006]Cancer Commun. 1991 Jul; 3(7):207-12.
[Cancer Commun. 1991]Genome Biol. 2002 Jul 15; 3(8):SOFTWARE0003.
[Genome Biol. 2002]Nucleic Acids Res. 2002 Feb 15; 30(4):e15.
[Nucleic Acids Res. 2002]Bioinformatics. 2001 Jun; 17(6):520-5.
[Bioinformatics. 2001]Nat Rev Genet. 2001 Jun; 2(6):418-27.
[Nat Rev Genet. 2001]Stat Med. 1990 Jul; 9(7):811-8.
[Stat Med. 1990]Anal Biochem. 1976 May 7; 72():248-54.
[Anal Biochem. 1976]